Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial.

Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E.

Mol Autism. 2012 Dec 5;3(1):16. doi: 10.1186/2040-2392-3-16.

2.

Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth.

Anagnostou E, Soorya L, Brian J, Dupuis A, Mankad D, Smile S, Jacob S.

Brain Res. 2014 Sep 11;1580:188-98. doi: 10.1016/j.brainres.2014.01.049. Epub 2014 Feb 5. Review.

PMID:
24508578
3.

The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial.

Guastella AJ, Gray KM, Rinehart NJ, Alvares GA, Tonge BJ, Hickie IB, Keating CM, Cacciotti-Saija C, Einfeld SL.

J Child Psychol Psychiatry. 2015 Apr;56(4):444-52. doi: 10.1111/jcpp.12305. Epub 2014 Aug 2.

PMID:
25087908
4.

The effect of intranasal oxytocin versus placebo treatment on the autonomic responses to human sounds in autism: a single-blind, randomized, placebo-controlled, crossover design study.

Lin IF, Kashino M, Ohta H, Yamada T, Tani M, Watanabe H, Kanai C, Ohno T, Takayama Y, Iwanami A, Kato N.

Mol Autism. 2014 Feb 28;5(1):20. doi: 10.1186/2040-2392-5-20.

5.

Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: a randomized trial.

Watanabe T, Abe O, Kuwabara H, Yahata N, Takano Y, Iwashiro N, Natsubori T, Aoki Y, Takao H, Kawakubo Y, Kamio Y, Kato N, Miyashita Y, Kasai K, Yamasue H.

JAMA Psychiatry. 2014 Feb;71(2):166-75. doi: 10.1001/jamapsychiatry.2013.3181.

PMID:
24352377
6.

Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial.

Quintana DS, Westlye LT, Hope S, Nærland T, Elvsåshagen T, Dørum E, Rustan Ø, Valstad M, Rezvaya L, Lishaugen H, Stensønes E, Yaqub S, Smerud KT, Mahmoud RA, Djupesland PG, Andreassen OA.

Transl Psychiatry. 2017 May 23;7(5):e1136. doi: 10.1038/tp.2017.103.

7.

Oxytocin for Male Subjects with Autism Spectrum Disorder and Comorbid Intellectual Disabilities: A Randomized Pilot Study.

Munesue T, Nakamura H, Kikuchi M, Miura Y, Takeuchi N, Anme T, Nanba E, Adachi K, Tsubouchi K, Sai Y, Miyamoto K, Horike S, Yokoyama S, Nakatani H, Niida Y, Kosaka H, Minabe Y, Higashida H.

Front Psychiatry. 2016 Jan 21;7:2. doi: 10.3389/fpsyt.2016.00002. eCollection 2016.

8.

Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism.

Parker KJ, Oztan O, Libove RA, Sumiyoshi RD, Jackson LP, Karhson DS, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, Garner JP, Hardan AY.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124. doi: 10.1073/pnas.1705521114. Epub 2017 Jul 10.

10.

Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial.

Kosaka H, Okamoto Y, Munesue T, Yamasue H, Inohara K, Fujioka T, Anme T, Orisaka M, Ishitobi M, Jung M, Fujisawa TX, Tanaka S, Arai S, Asano M, Saito DN, Sadato N, Tomoda A, Omori M, Sato M, Okazawa H, Higashida H, Wada Y.

Transl Psychiatry. 2016 Aug 23;6(8):e872. doi: 10.1038/tp.2016.152.

11.

A 12-week randomized controlled trial of twice-daily intranasal oxytocin for social cognitive deficits in people with schizophrenia.

Jarskog LF, Pedersen CA, Johnson JL, Hamer RM, Rau SW, Elliott T, Penn DL.

Schizophr Res. 2017 Jul;185:88-95. doi: 10.1016/j.schres.2017.01.008. Epub 2017 Jan 13.

PMID:
28094169
12.

A double-blind randomized controlled trial of oxytocin nasal spray and social cognition training for young people with early psychosis.

Cacciotti-Saija C, Langdon R, Ward PB, Hickie IB, Scott EM, Naismith SL, Moore L, Alvares GA, Redoblado Hodge MA, Guastella AJ.

Schizophr Bull. 2015 Mar;41(2):483-93. doi: 10.1093/schbul/sbu094. Epub 2014 Jun 23.

13.

A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome.

Einfeld SL, Smith E, McGregor IS, Steinbeck K, Taffe J, Rice LJ, Horstead SK, Rogers N, Hodge MA, Guastella AJ.

Am J Med Genet A. 2014 Sep;164A(9):2232-9. doi: 10.1002/ajmg.a.36653. Epub 2014 Jun 30.

PMID:
24980612
14.

Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB.

Biol Psychiatry. 2010 Apr 1;67(7):692-4. doi: 10.1016/j.biopsych.2009.09.020. Epub 2009 Nov 7.

PMID:
19897177
15.

Clinical and neural effects of six-week administration of oxytocin on core symptoms of autism.

Watanabe T, Kuroda M, Kuwabara H, Aoki Y, Iwashiro N, Tatsunobu N, Takao H, Nippashi Y, Kawakubo Y, Kunimatsu A, Kasai K, Yamasue H.

Brain. 2015 Nov;138(Pt 11):3400-12. doi: 10.1093/brain/awv249. Epub 2015 Sep 3.

PMID:
26336909
16.

Oxytocin administration enhances controlled social cognition in patients with schizophrenia.

Woolley JD, Chuang B, Lam O, Lai W, O'Donovan A, Rankin KP, Mathalon DH, Vinogradov S.

Psychoneuroendocrinology. 2014 Sep;47:116-25. doi: 10.1016/j.psyneuen.2014.04.024. Epub 2014 May 27. Erratum in: Psychoneuroendocrinology. 2015 Feb;52:13.

17.

The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial.

Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ.

Mol Psychiatry. 2016 Sep;21(9):1225-31. doi: 10.1038/mp.2015.162. Epub 2015 Oct 27.

18.

Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism.

Aoki Y, Yahata N, Watanabe T, Takano Y, Kawakubo Y, Kuwabara H, Iwashiro N, Natsubori T, Inoue H, Suga M, Takao H, Sasaki H, Gonoi W, Kunimatsu A, Kasai K, Yamasue H.

Brain. 2014 Nov;137(Pt 11):3073-86. doi: 10.1093/brain/awu231. Epub 2014 Aug 22.

PMID:
25149412
19.

The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study.

Woolley JD, Arcuni PA, Stauffer CS, Fulford D, Carson DS, Batki S, Vinogradov S.

Psychopharmacology (Berl). 2016 Jul;233(13):2571-80. doi: 10.1007/s00213-016-4308-8. Epub 2016 May 3.

PMID:
27137199
20.

Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial.

King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L, Hollander E, Bregman JD, Anagnostou E, Robinson F, Sullivan L, Hirtz D.

JAMA Pediatr. 2013 Nov;167(11):1045-52. doi: 10.1001/jamapediatrics.2013.2698.

Supplemental Content

Support Center